Investors

The leading position in the Russian pharmaceutical market is the result of the painstaking work of all departments of PJSC "Kraspharma". Undoubtedly, competitive advantages are achieved, first of all, by the quality and availability of manufactured products - tangible resources that bring profit. Moreover, the stable growth and reputation of the company are determined by the openness of our business, which makes PJSC "Kraspharma" attractive for investments.

PJSC "Krasfarma" - the leading Russian pharmaceutical company, manufacturer of hospital drugs. The product portfolio of PJSC "Kraspharma" includes parenteral antibiotics in the dosage forms "powder for preparation of the solution for injections", "lyophilisate for preparation of the solution for injection", anti-TB drugs, fibrinolysis inhibitors (hemostatic agents), osmotic diuretics, as well as a wide range of infusion solutions, including those used to restore the water-salt balance, antishock fluids and solutions that have a detoxification effect.

PJSC "Krasfarma" is a public joint-stock company that supports advanced standards of corporate governance and disclosure. The Company's shares are listed on the Russian stock exchange.

Constantly working to improve corporate policy and increase information transparence, we try to provide investors and shareholders with comprehensive data on the Company's activities, ensuring the availability and usability of information.

Некоторые материалы этого раздела сайта могут быть доступны только после процедуры авторизации